These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3112715)

  • 1. [Evaluation of the specific activity of hyperimmune anti-Pseudomonas aeruginosa human plasma in an experiment].
    Podgornaia LG; Shinkarenko AA; Krokhina MA; Dziuban NF; D'iachenko VF
    Patol Fiziol Eksp Ter; 1987; (2):70-2. PubMed ID: 3112715
    [No Abstract]   [Full Text] [Related]  

  • 2. Study of Pseudomonas haemolysin. III. Properties of antilysin serum.
    Lochmann O; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1975; 19(2):224-9. PubMed ID: 809503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa antibodies in human plasma.
    Doi T; Yoshioka M; Nakajima T
    Jpn J Exp Med; 1976 Jun; 46(3):149-54. PubMed ID: 60502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Protective action of various antibody preparations in experimental bacterial sepsis].
    Trautmann M; Brückner O; Hofstaetter T; Seiler FR; Hahn H
    Beitr Infusionther Klin Ernahr; 1982; 9():155-65. PubMed ID: 6816213
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
    Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
    Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Donor plasma with anti-Pseudomonas aeruginosa activity as a directed-action preparation].
    Nazarchuk LV
    Vrach Delo; 1987 Jul; (7):96-8. PubMed ID: 3114958
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of the protective properties of native and sorbed Pseudomonas aeruginosa anatoxins].
    Dziuban NF
    Mikrobiol Zh (1978); 1983; 45(6):85-7. PubMed ID: 6443863
    [No Abstract]   [Full Text] [Related]  

  • 9. [The protective effect of anti-Pseudomonas blood preparations].
    Nazarchuk LV; Koval' AI
    Fiziol Zh (1994); 2001; 47(6):55-7. PubMed ID: 11962093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Protective effect of Pseudomonas-specific immunoglobulin from the rabbit and of active immunization in experimental Pseudomonas sepsis in mice].
    Trautmann M; Brückner O; Hahn H
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jul; 252(3):370-83. PubMed ID: 6215803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive hemagglutination reaction using formalinized sheep erythrocytes treated with tannic acid and coated with exotoxin of Pseudomonas aeruginosa.
    Takeshi K; Homma JY
    Jpn J Exp Med; 1978 Dec; 48(6):497-501. PubMed ID: 108439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of properties of Pseudomonas aeruginosa recombinant outer membrane protein F (OprF)].
    Zlygostev SA; Gataullin AG; Kaloshin AA; Mikhaĭlova NA; Zverev VV
    Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):43-7. PubMed ID: 17297879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-pseudomonas activity of anti-lipopolysaccharide hyperimmune equine plasma.
    Wells M; Gaffin SL
    Clin Exp Immunol; 1987 Apr; 68(1):86-92. PubMed ID: 3115643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of a polyvalent erythrocyte diagnostic agent for determining antibodies to Pseudomonas aeruginosa in clinical practice].
    Aleksandrova IA; Titova TI; Aleksandrov AD; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Jan; (1):46-50. PubMed ID: 2496541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The production and use of plasma against Pseudomonas aeruginosa infection].
    Popov SD; Ryzhkov SV; Stanislavskiĭ ES; Plakhotnikov AIa; Gurevich KIa; Sergienko AI; Zaĭchik VI; Popova NN; Fedorova GM; Edvabnaia LS
    Voen Med Zh; 1990 Dec; (12):30-1. PubMed ID: 2127965
    [No Abstract]   [Full Text] [Related]  

  • 19. [Production of a hyperimmune antitoxic donor plasma against Pseudomonas aeruginosa].
    Krokhina MA; Davatdarova GM; Cherkas GP; Podgornaia LG; Shinkarenko AA
    Zh Mikrobiol Epidemiol Immunobiol; 1980 Sep; (9):78-83. PubMed ID: 6778040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive hemagglutination reaction test using formalinized sheep erythrocytes treated with tannic acid and coated with proteast or elastase of Pseudomonas aeruginosa.
    Homma JY; Tomiyama T; Sano H; Hirao Y; Saku K
    Jpn J Exp Med; 1975 Oct; 45(5):361-5. PubMed ID: 817055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.